Mark Rosenblum

Mark Rosenblum

Directeur Général chez
Salarius Pharmaceuticals LLC

Fortune : 22 385 $ au 30/09/2026

72 ans
Health Technology
Process Industries
Commercial Services

Profil

Mark J.
Rosenblum
currently serves as Executive VP, Chief Executive & Financial Officer at Salarius Pharmaceuticals LLC starting in 2025.
He is a Member of The American Institute of Certified Public Accountants.
Since 2019, he has been Chief Financial Officer & Executive Vice President at Decoy Therapeutics, Inc. Formerly, he was Chairman & Chief Executive Officer at ActiveCare, Inc. from 2017 to 2019.
From 1985 to 2003, he was Chief Accounting Officer, VP & Controller at Wellman, Inc. He was Chief Financial Officer & Secretary at Hemobiotech, Inc. from 2005 to 2009.
From 2010 to 2014, he held the roles of Chief Financial Officer, Secretary & Senior VP at Advaxis, Inc. He was Chief Financial Officer at Vaneltix Pharma, Inc. from 2014 to 2015.
He was Chief Executive & Financial Officer at Salarius Pharmaceuticals, Inc. in 2025.
He was a Member of the South Carolina Association of Certified Public Accountants.
Education includes undergraduate and graduate degrees from the University of South Carolina.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
0,62 %
31/08/2026 11 363 ( 0,62 % ) 22 385 $ 30/09/2026

Postes actifs de Mark Rosenblum

SociétésPosteDébut
Corporate Officer/Principal -
Directeur Général 17/08/2025

Anciens postes connus de Mark Rosenblum

SociétésPosteFin
ACTIVECARE INC Directeur Général 01/03/2019
Directeur Financier/CFO 01/07/2015
AYALA PHARMACEUTICALS, INC. Directeur Financier/CFO 01/04/2014
Directeur Financier/CFO 31/12/2009
Comptroller/Controller/Auditor 01/06/2003
Voir l'expérience en détail de Mark Rosenblum

Formation de Mark Rosenblum

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

49

Relations au 1er degré

10

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées10

Process Industries

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Mark Rosenblum
🔇